Xcout Intel
Brenus Pharma
Brenus Pharma is a pioneering clinical-stage biotech company headquartered in Clermont-Ferrand, France. The firm focuses on developing innovative immunotherapies aimed at preventing cancer recurrence and addressing solid tumors.
Subscribe to see Brenus Pharma’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Brenus Pharma at a glance
Brenus Pharma is a biotechnology company headquartered in France. Its most recent funding round, Series A, raised $12.6M in July 2026. Xcout tracks 22 named people at Brenus Pharma, including Paul Bravetti (Chief Executive Officer).
Brenus Pharma leadership
- Paul BravettiChief Executive Officer
- Eric DessertennePresident and Chairman
- Aymeric BordetChief Financial Officer
- Benoit PinteurCO-Founder & CSO
- Jacques GardetteCo-Founder
- Herve GisserotGeneral Manager of CSL Vifor
16 more named people on record for Brenus Pharma, with roles, board committees and tenure — see the full roster →
Brenus Pharma funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $12.6M | 9 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Brenus Pharma competitors
A few of Brenus Pharma's closest competitors — see the full list of competitors and alternatives →
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Brenig Therapeutics, Inc. is a clinical-stage biotechnology and drug development company focused on advancing small-molecule therapies.
Hephaitos Pharma is a preclinical-stage biotech company founded in 2018 and headquartered in Orsay, France. Backed by investors such as Elaia and the Fournier-Majoie Foundation, the firm focuses on developing the next generation of immunotherapies for cancer treatment. It operates as a privately held developer in the European life sciences sector.
Apmonia Therapeutics is a biotechnology company headquartered in Reims, France, committed to developing innovative therapeutic strategies for multiple types of cancer. Operating from its headquarters on Esplanade Roland, the firm advances oncology-focused drug candidates to target tumor progression. It is an active participant in the French biotech and life sciences ecosystem.
Agenus Inc. is a biotechnology company headquartered in Lexington, Massachusetts, focused on the discovery and development of better immunotherapies and cancer treatments.
Lytix Biopharma is a clinical-stage biotechnology company developing oncolytic molecule therapies to treat superficial and deep-seated tumors. The company focuses on the neoadjuvant setting, providing first-in-class immunotherapies designed to destroy cancer cell membranes and stimulate a broad immune response.
Get Brenus Pharma's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Brenus Pharma in Xcout Intel
- 22 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access